Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigatio ...
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders should be happy to see the share price up 11% in the ...
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $23.11 which represents a decrease of $-2.96 or -11.35% from the prior close of $26.07. The stock opened at $26.15 and ...
Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...
Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...
Charles Schwab Investment Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback